AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20082624 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide controlled-release (CR) tablets plus acarbose
Number of subjects: 40
Study 18392503 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash with oxygenating and antimicrobial substances
Number of subjects: 50
Study 18392503 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 50
Study 15801331 — intervention group
Group type: EXPERIMENTAL
Intervention: LY333013
Number of subjects: 50
Study 15801331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12424783 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined individual telephone and in-person group support and education for 13 months
Number of subjects: 125
Study 12424783 — intervention group
Group type: COMPARATOR
Intervention: Telephone-only individual support and education for 13 months
Number of subjects: 125
Study 12424783 — intervention group
Group type: COMPARATOR
Intervention: One-time mailed educational information
Number of subjects: 125
Study 12424783 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 125
Study 10915227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff width:arm circumference ratio of 46.4%
Number of subjects: 50
Study 10915227 — intervention group
Group type: COMPARATOR
Intervention: Standard 13cm-wide cuff
Number of subjects: 50
Study 8652324 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% human albumin (HA)
Number of subjects: 40
Study 8652324 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5% dextran 40 (Dxt 40)
Number of subjects: 40
Study 8652324 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethylstarch 200 (HES)
Number of subjects: 40
Study 8652324 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% dextran 60 (Dxt 60)
Number of subjects: 40
Study 8652324 — intervention group
Group type: EXPERIMENTAL
Intervention: modified fluid gelatin (Gel)
Number of subjects: 40
Study 1647149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (80 mg/m2, day 1)/Etoposide (100 mg/m2, day 1, 3, 5) (PE)
Number of subjects: 92
Study 1647149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (80 mg/m2, day 1)/Etoposide (100 mg/m2, day 1, 3, 5)/Ifosfamide (2 g/m2, day 1, 2, 3) (PEI)
Number of subjects: 92
Study 6395435 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 30
Study 6395435 — intervention group
Group type: COMPARATOR
Intervention: Control group (no desmopressin)
Number of subjects: 30
Study 12270864 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 36
Study 12270864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29853320 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 375
Study 26537943 — intervention group
Group type: EXPERIMENTAL
Intervention: High-DHA diet (1% of total fatty acids)
Number of subjects: 104
Study 26537943 — intervention group
Group type: COMPARATOR
Intervention: Standard-DHA diet (0.2-0.3% of total fatty acids as DHA)
Number of subjects: 104
Study 24811095 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined monitoring (ultrasound plus serum estradiol monitoring, UHM group)
Number of subjects: 416
Study 24811095 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound monitoring only (UM group)
Number of subjects: 416
Study 22652942 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone, 60 mg/d for 5 days, tapered for 5 days
Number of subjects: 829
Study 19451806 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (specifically ezetimibe/simvastatin)
Number of subjects: 0
Study 19451806 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 17565287 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Interaction Project (VIP)
Number of subjects: 99
Study 17565287 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study 16204002 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients (n=2050)
Number of subjects: 4626
Study 16204002 — intervention group
Group type: COMPARATOR
Intervention: Male patients (n=2576)
Number of subjects: 4626
Study 16204002 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe leucopenia during chemotherapy
Number of subjects: 4626
Study 16204002 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who developed severe leucopenia within the first two cycles of chemotherapy
Number of subjects: 4626
Study 12352809 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth dose of HepB
Number of subjects: 550
Study 12352809 — intervention group
Group type: COMPARATOR
Intervention: No birth dose of HepB
Number of subjects: 550
Study 12352809 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 550
Study 10497976 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives of soldiers positive for cysticercosis and taeniasis markers
Number of subjects: 1000
Study 10497976 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives of positive soldiers
Number of subjects: 1000
Study 10497976 — intervention group
Group type: COMPARATOR
Intervention: Family members of the control group
Number of subjects: 1000
Study 10497976 — intervention group
Group type: EXPERIMENTAL
Intervention: Soldiers
Number of subjects: 1000
Study 10497976 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives
Number of subjects: 1000
Study 10497976 — intervention group
Group type: EXPERIMENTAL
Intervention: Soldiers and relatives
Number of subjects: 1000
Study 7843758 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg)
Number of subjects: 20
Study 7843758 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg)
Number of subjects: 20
Study 7843758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7843758 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 20
Study 7843758 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 20
Study 7843758 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine and Lisinopril
Number of subjects: 20
Study 2236929 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 500 micrograms daily
Number of subjects: 10
Study 2236929 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 1,000 micrograms daily
Number of subjects: 10
Study 2236929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 406627 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg methylphenidate
Number of subjects: 12
Study 406627 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg methylphenidate
Number of subjects: 12
Study 406627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 406627 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg methylphenidate (open trial)
Number of subjects: 12
Study 30379568 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab maintenance therapy
Number of subjects: 499
Study 30379568 — intervention group
Group type: COMPARATOR
Intervention: Continuation of first-line chemotherapy
Number of subjects: 499
Study 28802596 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-phase remote ischemic preconditioning (ERIPC)
Number of subjects: 65
Study 28802596 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-phase remote ischemic preconditioning (LRIPC)
Number of subjects: 65
Study 28802596 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 65
Study 24638908 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with long‐chain ω‐3 polyunsaturated fatty acids (350 mg DHA + 650 mg EPA)
Number of subjects: 4203
Study 24638908 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with lutein + zeaxanthin (10 mg lutein + 2 mg zeaxanthin)
Number of subjects: 4203
Study 24638908 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of long‐chain ω‐3 fatty acids and lutein + zeaxanthin
Number of subjects: 4203
Study 24638908 — intervention group
Group type: COMPARATOR
Intervention: Matching placebos
Number of subjects: 4203
Study 23651231 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (800 mg/day)
Number of subjects: 42
Study 23651231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20175973 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip strengthening (physiotherapist-supervised home exercise program targeting hip abductor and adductor muscles for 12 weeks)
Number of subjects: 89
Study 20175973 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89
Study 20175973 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip strengthening
Number of subjects: 89
Study 18359332 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 0
Study 18359332 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid
Number of subjects: 0
Study 18359332 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0
Study 18359332 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0
Study 18359332 — intervention group
Group type: COMPARATOR
Intervention: Sulindac
Number of subjects: 0
Study 18359332 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 0
Study 16781230 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1885
Study 16781230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1885
Study 12680858 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3.7 g n-3 PUFA/day)
Number of subjects: 83
Study 12680858 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 83
Study 10887922 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% all‐trans‐retinoic acid (tretinoin) ophthalmic emulsion
Number of subjects: 22
Study 10887922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9197524 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (50 or 500 mg/day) for 5 years
Number of subjects: 397
Study 9197524 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene supplementation (0 or 15 mg/day) for 5 years (discontinued after initial recruitment)
Number of subjects: 397
Study 8110565 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural morphine 0.75 microgram kg‐1 with an additional dose administered 24 h later (group M)
Number of subjects: 30
Study 8110565 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural fentanyl 2 micrograms kg‐1 followed by continuous extradural infusion of fentanyl 5 micrograms kg‐1 day‐1 (group F)
Number of subjects: 30
Study 8110565 — intervention group
Group type: COMPARATOR
Intervention: Continuous extradural infusion of fentanyl 5 micrograms kg‐1 day‐1
Number of subjects: 30
Study 3050510 — intervention group
Group type: EXPERIMENTAL
Intervention: Isaxonine
Number of subjects: 20
Study 31045852 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to 1,3-butadiene during the second trimester
Number of subjects: 243
Study 31045852 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to meta/para-xylene during the second trimester
Number of subjects: 243
Study 31045852 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to traffic-related air toxics
Number of subjects: 243
Study 28427544 — intervention group
Group type: EXPERIMENTAL
Intervention: WBVT (whole-body vibration training)
Number of subjects: 74
Study 28427544 — intervention group
Group type: COMPARATOR
Intervention: Control (squat training without WBVT)
Number of subjects: 74
Study 28427544 — intervention group
Group type: EXPERIMENTAL
Intervention: WBVT
Number of subjects: 74
Study 28427544 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 74
Study 24412895 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and intra-articular glucocorticosteroid injections with adalimumab
Number of subjects: 85
Study 24412895 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate and intra-articular glucocorticosteroid injections with placebo
Number of subjects: 85
Study 24259786 — intervention group
Group type: EXPERIMENTAL
Intervention: Stomatognathic alignment exercise
Number of subjects: 14
Study 24259786 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14
Study 21416146 — intervention group
Group type: EXPERIMENTAL
Intervention: EE estimated by individual equation (EE(mag‐Val‐INDIV))
Number of subjects: 11
Study 21416146 — intervention group
Group type: EXPERIMENTAL
Intervention: EE estimated by group equation (EE(mag‐val‐GROUP))
Number of subjects: 11
Study 21416146 — intervention group
Group type: EXPERIMENTAL
Intervention: Group equation (EE(mag‐val‐GROUP))
Number of subjects: 11
Study 19273714 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-docetaxel (GD)
Number of subjects: 305
Study 19273714 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine-docetaxel (CD)
Number of subjects: 305
Study 17907739 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand sanitizer
Number of subjects: 383
Study 17907739 — intervention group
Group type: COMPARATOR
Intervention: Soap and water (hand washing)
Number of subjects: 383
Study 15147076 — intervention group
Group type: EXPERIMENTAL
Intervention: STRESSEN
Number of subjects: 20
Study 15147076 — intervention group
Group type: COMPARATOR
Intervention: arginine glutamate
Number of subjects: 20
Study 11500582 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-atrial pacing (BAP)
Number of subjects: 118
Study 11500582 — intervention group
Group type: COMPARATOR
Intervention: No atrial pacing (NAP)
Number of subjects: 118
Study 8831082 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic fresh frozen plasma (20 ml/kg followed by 10 ml/kg after 24 h)
Number of subjects: 776
Study 8831082 — intervention group
Group type: EXPERIMENTAL
Intervention: Inert gelatin plasma substitute (Gelofusine)
Number of subjects: 776
Study 8831082 — intervention group
Group type: COMPARATOR
Intervention: Control management with a maintenance infusion of 10% dextrose
Number of subjects: 776
Study 8831082 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic fresh frozen plasma
Number of subjects: 776
Study 1282183 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg nicorandil
Number of subjects: 38
Study 1282183 — intervention group
Group type: COMPARATOR
Intervention: 0.8 mg nitroglycerin
Number of subjects: 38
Study 1282183 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 or 20 mg nicorandil
Number of subjects: 38
Study 1282183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 4040500 — intervention group
Group type: EXPERIMENTAL
Intervention: OKY‐1581 (thromboxane A2 synthetase inhibitor); 2-3 micrograms/kg per min for 48 hours
Number of subjects: 55
Study 4040500 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment with OKY‐1581)
Number of subjects: 55
Study 4040500 — intervention group
Group type: EXPERIMENTAL
Intervention: OKY‐1581 treatment
Number of subjects: 55
Study 31142344 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum contraceptive counseling and immediate postpartum intra-uterine device (PPIUD) insertion services
Number of subjects: 75587
Study 31142344 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling due to the intervention
Number of subjects: 75587
Study 29474291 — intervention group
Group type: EXPERIMENTAL
Intervention: Icon™ reusable underwear
Number of subjects: 70
Study 29474291 — intervention group
Group type: COMPARATOR
Intervention: Disposable pads
Number of subjects: 70
Study 26175459 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic curriculum in two 3-hour sessions
Number of subjects: 1378
Study 26175459 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1378
Study 24685536 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised bias modification positive appraisal training (CBM)
Number of subjects: 60
Study 24685536 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-delivered cognitive behavioural therapy session (CB-Education)
Number of subjects: 60
Study 24685536 — intervention group
Group type: COMPARATOR
Intervention: No intervention monitoring control condition (Control)
Number of subjects: 60
Study 23103036 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 7021
Study 23103036 — intervention group
Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 7021
Study 19435959 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 128
Study 19435959 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 128
Study 19435959 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate + Metformin
Number of subjects: 128
Study 19435959 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 128
Study 17898698 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated GFR combining plasma creatinine (Pcr) and cystatin C (cysC) measurements
Number of subjects: 567
Study 17898698 — intervention group
Group type: COMPARATOR
Intervention: Modified MDRD equation for Chinese patients
Number of subjects: 567
Study 17898698 — intervention group
Group type: COMPARATOR
Intervention: Estimate combining cysC and modified MDRD calculations
Number of subjects: 567
Study 17898698 — intervention group
Group type: COMPARATOR
Intervention: Equation based solely on cystatin C (cysC)
Number of subjects: 567
Study 15151712 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Menopausal Gonadotrophin (HMG)
Number of subjects: 280
Study 15151712 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH (rFSH)
Number of subjects: 280
Study 15151712 — intervention group
Group type: EXPERIMENTAL
Intervention: Conception cycles
Number of subjects: 280
Study 15151712 — intervention group
Group type: COMPARATOR
Intervention: Non-conception cycles
Number of subjects: 280
Study 11685031 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (1 mg/kg every 8 hours for 14 days)
Number of subjects: 31
Study 11685031 — intervention group
Group type: COMPARATOR
Intervention: Control (H2-receptor antagonists and gastrokinetic drugs)
Number of subjects: 31
Study 9699091 — intervention group
Group type: EXPERIMENTAL
Intervention: CWT 3 days/week (n = 15)
Number of subjects: 27
Study 9699091 — intervention group
Group type: COMPARATOR
Intervention: No formal exercise (control) (n = 12)
Number of subjects: 27
Study 10411814 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple testing
Number of subjects: 358
Study 10411814 — intervention group
Group type: COMPARATOR
Intervention: Two-step testing
Number of subjects: 358
Study 2239303 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-16 alone
Number of subjects: 116
Study 2239303 — intervention group
Group type: COMPARATOR
Intervention: VP-16 combined with other anti-tumor agents
Number of subjects: 116
Study 657893 — intervention group
Group type: EXPERIMENTAL
Intervention: Training condition (visual-spatial disembedding training)
Number of subjects: 93
Study 657893 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no training)
Number of subjects: 93
Study 31505082 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (exact dosage not specified)
Number of subjects: 1536
Study 31505082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1536
Study 31505082 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine and Placebo (combined analysis)
Number of subjects: 1536
Study 30801948 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF (In Vitro Fertilisation)
Number of subjects: 6191
Study 30801948 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF-AO (In Vitro Fertilisation with Autologous Oocytes)
Number of subjects: 6191
Study 30801948 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF-OD (In Vitro Fertilisation with Oocyte Donation)
Number of subjects: 6191
Study 30801948 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple pregnancy as an intermediate factor
Number of subjects: 6191
Study 28197680 — intervention group
Group type: EXPERIMENTAL
Intervention: Condolence letter
Number of subjects: 242
Study 28197680 — intervention group
Group type: COMPARATOR
Intervention: No condolence letter
Number of subjects: 242
Study 25772750 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D TV watching
Number of subjects: 72
Study 25772750 — intervention group
Group type: COMPARATOR
Intervention: 2D TV watching
Number of subjects: 72
Study 24026162 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracolumbosacral orthosis
Number of subjects: 0
Study 24026162 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 0
Study 22021867 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive accreditation intervention implemented over two and a half winter sporting seasons, which includes multiple elements designed to decrease alcohol supply, cease provision of cheap alcohol, increase availability of non-alcoholic beverages, remove high alcohol drinks, and cease drinking games.
Number of subjects: 0
Study 22021867 — intervention group
Group type: COMPARATOR
Intervention: Printed materials on topics unrelated to alcohol (Control group).
Number of subjects: 0
Study 19267963 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched-taper single-cone obturation
Number of subjects: 66
Study 19267963 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral condensation obturation
Number of subjects: 66
Study 19267963 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil obturation
Number of subjects: 66
Study 17112804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (20 mg orally)
Number of subjects: 8
Study 17112804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe glucuronide (after rifampin coadministration)
Number of subjects: 8
Study 14678952 — intervention group
Group type: EXPERIMENTAL
Intervention: IDPN + exercise
Number of subjects: 6
Study 14678952 — intervention group
Group type: COMPARATOR
Intervention: IDPN only
Number of subjects: 6
Study 11248608 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg once daily
Number of subjects: 1529
Study 11248608 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine IR 2 mg twice daily
Number of subjects: 1529
Study 11248608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1529